设计,合成和评估了一系列同型异黄酮衍生物,作为潜在的多功能抗阿尔茨海默氏病药物对胆碱酯酶和单胺氧化酶的抑制活性。其中,化合物16显示出中等的乙酰胆碱酯酶(AChE)抑制活性(eeAChE IC 50 = 0.89±0.02μM; hAChE IC 50 = 0.657±0.002μM )和显着的单胺氧化酶B(MAO-B)抑制活性(hMAO-B IC 50 = 0.0372±0.0002μM)。AChE的动力学分析,对MAO-B的抑制和分子模型研究表明,化合物16是AChE的双重结合位点抑制剂,是MAO-B的非竞争性抑制剂。再说16可以在体外穿透血脑屏障(BBB)。最重要的是,口服16剂没有明显的急性毒性迹象,并且可以显着逆转东pol碱引起的小鼠记忆障碍。这些结果表明,化合物16是有前途的多功能药物候选物,具有治疗阿尔茨海默氏病的潜在作用。
Direct access to functionalized 4-nitromethyl-chromenes via a domino reaction under catalyst-free conditions
作者:Wengang Xu、Qingcui Li、Wangwang Wang、Hua Zheng、Fanglin Zhang、Yunxing Hu
DOI:10.1039/c5ra11333d
日期:——
A simple and practical tandem reaction has been established to synthesize functionalized 4-(nitromethyl)-4H-chromenes. Most products were obtained in medium to good yields. Further, chromeno[4,3-b]chromene, an important structure, was easily obtained via this strategy.
Notes: Reactions of Several 4-Pyrones Catalyzed by Potassium Acetate and Trifluoroacetic Acid
作者:L Woods、P Dix
DOI:10.1021/jo01090a604
日期:1959.8
Synthesis and antifungal activity of some 3-benzylidenechroman-4-ones, 3-benzylidenethiochroman-4-ones and 2-benzylidene-1-tetralones
作者:T Al Nakib、V Bezjak、MJ Meegan、R Chandy
DOI:10.1016/0223-5234(90)90010-z
日期:1990.6
AL, NAKIB T.;BEZJAK, V.;MEEGAN, M. J.;CHANDY, R., EUR. J. MED. CHEM., 25,(1990) N, C. 455-462
作者:AL, NAKIB T.、BEZJAK, V.、MEEGAN, M. J.、CHANDY, R.
DOI:——
日期:——
Synthesis and pharmacological evaluation of multi-functional homoisoflavonoid derivatives as potent inhibitors of monoamine oxidase B and cholinesterase for the treatment of Alzheimer's disease
作者:Qiao-Hong Liu、Jia-Jia Wu、Fan Li、Pei Cai、Xue-Lian Yang、Ling-Yi Kong、Xiao-Bing Wang
DOI:10.1039/c7md00199a
日期:——
homoisoflavonoid derivatives was designed, synthesized and evaluated as potential multi-functional anti-Alzheimer's agents for their inhibitory activity on cholinesterase and monoamine oxidase. Among them, compound 16 showed moderate acetylcholinesterase (AChE) inhibitory activity (eeAChE IC50 = 0.89 ± 0.02 μM; hAChE IC50 = 0.657 ± 0.002 μM) and significant monoamine oxidase B (MAO-B) inhibitory activity (hMAO-B IC50
设计,合成和评估了一系列同型异黄酮衍生物,作为潜在的多功能抗阿尔茨海默氏病药物对胆碱酯酶和单胺氧化酶的抑制活性。其中,化合物16显示出中等的乙酰胆碱酯酶(AChE)抑制活性(eeAChE IC 50 = 0.89±0.02μM; hAChE IC 50 = 0.657±0.002μM )和显着的单胺氧化酶B(MAO-B)抑制活性(hMAO-B IC 50 = 0.0372±0.0002μM)。AChE的动力学分析,对MAO-B的抑制和分子模型研究表明,化合物16是AChE的双重结合位点抑制剂,是MAO-B的非竞争性抑制剂。再说16可以在体外穿透血脑屏障(BBB)。最重要的是,口服16剂没有明显的急性毒性迹象,并且可以显着逆转东pol碱引起的小鼠记忆障碍。这些结果表明,化合物16是有前途的多功能药物候选物,具有治疗阿尔茨海默氏病的潜在作用。